Adverse event of ruxolitinib cream: a real-world analysis based on FDA adverse event reporting system from 2021 to 2024.

Background: Ruxolitinib cream, a topical Janus kinase (JAK) inhibitor, is a widely used treatment for various dermatological diseases. This study employs the FDA Adverse Event Reporting System (FAERS) database to examine adverse events (AEs) associated with ruxolitinib cream.

Methods: This study employed disproportionate analysis methods, including reported odds ratio and proportional reporting ratio, to collate AEs reported from the fourth quarter of 2021 to the first quarter of 2024.

Elsberg syndrome - A systematic review of existing scientific literature from 2000 - 2023.

Objective: To assess the clinical presentation, causative agents, and treatment outcomes in patients diagnosed with Elsberg syndrome (ES).

Methods: A thorough literature search was conducted on the mentioned topic using PRISMA guidelines via PubMed, Google Scholar, and SCOPUS. Articles published between 2000 and 2023 were included using advanced search and Boolean strategy.

Association between herpes zoster and Parkinson's disease and dementia: a systematic review and meta-analysis.

Objectives: This meta-analysis investigated the relationship between herpes zoster and the risk of dementia or Parkinson's disease by analyzing published clinical studies.

Methods: We systematically searched PubMed, Cochrane, Embase, and Web of Science Core Collection databases on April 25, 2024. Hazard ratios (HR) were used for statistical analyses.

Clinical study of short-term spinal cord stimulation for herpes zoster-associated pain.

Background: Zoster-associated neuralgia refers to neuropathic pain from herpes zoster, which can persist as postherpetic neuralgia (PHN). Preventing the progression to chronic PHN is crucial, yet optimal interventions is still not clear.

Objectives: This study evaluates the efficacy of short-term spinal cord stimulation (tSCS) in patients with subacute and chronic PHN.

Risk of adverse events after Omicron XBB-adapted BNT162b2 COVID-19 vaccination in the United States.

Background: Limited data exists regarding the safety of the COVID-19 2023-2024 vaccine formulations and whether the safety profiles differ from the original formulations. We evaluated the association between the BNT162b2 XBB COVID-19 vaccine and the risk of 20 pre-specified adverse events of special interest (AESIs).

Methods: We identified commercially-insured individuals in the US age ≥ 6 months who received the BNT162b2 XBB COVID-19 vaccine between September 11, 2023 and January 15, 2024 within the Optum pre-adjudicated database.

Detecting Monkeypox Virus by Immunohistochemistry.

Background: Mpox (formerly known as monkeypox), a zoonotic disease caused by Monkeypox virus (MPXV), has become an international outbreak since May 2022. Mpox often presents with a mild systemic illness and a characteristic vesiculopustular skin eruption. In addition to molecular testing, histopathology of cutaneous lesions usually shows distinctive findings, such as epidermal necrosis, balloon degeneration, papillary dermal edema, and focal dermal necrosis, which have proven helpful in the diagnosis of mpox.

[Herpes zoster : vaccination and management of satellite lesions in immunocompromised patients].

Shingles, also termed herpes zoster (HZ), is due to the reactivation of the varicella zoster virus (VZV) in a dorsal root nerve ganglion with an intra-axonal passage of the virus to a predetermined dermatome. The risk of HZ increases with age, as well as the morbidity risks. The most feared complication is post-herpetic neuralgia, defined as persisting pain sensations three months after the resolution of the skin lesions.

Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis.

Objectives: Describe tofacitinib safety from an integrated analysis of randomized controlled trials (RCTs) in patients with ankylosing spondylitis (AS).

Method: Pooled data from Phase 2 (NCT01786668; 04/2013-03/2015)/Phase 3 (NCT03502616; 06/2018-08/2020) RCTs in AS patients were analyzed (3 overlapping cohorts): 16-week placebo-controlled (tofacitinib 5 mg twice daily [BID] [n = 185]; placebo [n = 187]); 48-week only-tofacitinib 5 mg BID (n = 316); 48-week all-tofacitinib (≥ 1 dose of tofacitinib 2, 5, or 10 mg BID; n = 420). Baseline 10-year atherosclerotic cardiovascular disease (ASCVD) risk was determined in patients without history of ASCVD (48-week cohorts).

Community pharmacists' knowledge, beliefs, and perceived barriers toward vaccination services at community pharmacies: A cross-sectional study from Saudi Arabia.

Community pharmacists were recently authorized to provide vaccination services in Saudi Arabia. However, the implementation is still limited. Consequently, this study aimed to assess the knowledge, beliefs, and views of community pharmacists in the Qassim region regarding vaccines and vaccination services and to identify the barriers to providing such services.

Relationship Between Preoperative Serum Albumin and Uric Acid and One-year Cure Rate in Patients With Herpes Zoster.

Background: Herpes zoster (HZ) is a common condition that causes severe pain mostly in middle-aged and older adults. It is currently treated with a combination of medication and surgery. However, some patients do not experience complete pain relief even after surgery and often experience a period of mild pain until a complete cure.

Efficacy of Higher-Voltage Long-Duration Pulsed Radiofrequency for Spinal Zoster-Associated Pain: A Randomized Controlled Trial.

Background: High-voltage (65 V) long-duration pulsed radiofrequency (HL-PRF) is an effective method for managing zoster-associated pain (ZAP), though the limited efficacy of and high recurrence rates associated with the procedure present concerns.

Objectives: This study aimed to investigate the safety and effectiveness of a higher-voltage HL-PRF treatment based on the original procedure for ZAP in the spinal area.

Study Design: A prospective, randomized, controlled trial.

Serious infections and tuberculosis adversely impact outcomes of juvenile onset systemic lupus erythematosus in India.

Background: Infections are a major cause of morbidity and mortality in juvenile systemic lupus erythematosus (SLE). We assessed the incidence and risk factors for major infections in juvenile SLE.

Methods: A retrospective review of 225 patients of juvenile SLE (ACR 1997 criteria) with age <18 years visiting the rheumatology clinic at a single centre between 2000 to 2020 was done from case records and the hospital electronic health records.

Management of Herpes Zoster Ophthalmicus with Optic Neuritis and Cavernous Sinus Involvement: A Case Report.

Purpose: To report a treatment approach of a rare presentation of herpes zoster ophthalmicus (HZO) with optic neuropathy and oculomotor nerve palsy.

Methods: Report of one case.

Results: Multiple lesions involving the optic nerve and cavernous sinus were demonstrated on magnetic resonance imaging in a patient with a characteristic herpes zoster rash in the V1 dermatomal distribution.

Psychiatric Disorders and Their Impact on Herpes Zoster Incidence: Five Years of Data from Turkiye.

: This study investigates the relationship between psychiatric disorders and herpes zoster (HZ). Emergency and outpatient admissions to Kırşehir Education and Research Hospital between 2019 and 2023 were examined. Psychiatric disorders are known in the literature as one of the factors that weaken the immune system, thereby increasing the risk of infection.

Immune Response to an Adjuvanted Recombinant Zoster Vaccine in Japanese Patients with Rheumatoid Arthritis Receiving Upadacitinib (End Zoster-J Study): Study Protocol for an Exploratory Parallel Triple-Arm Prospective Trial.

: Janus kinase (JAK) inhibitors have emerged as a new class of disease-modifying anti-rheumatic drugs in the treatment of rheumatoid arthritis (RA). However, herpes zoster is one of the common adverse events of JAK inhibitors, including upadacitinib, which is especially high in Japanese patients with RA compared to those from Western countries. Recombinant zoster vaccine (Shingrix) is an adjuvanted subunit vaccine containing varicella-zoster virus (VZV) glycoprotein E (gE) that is effective in adults over 50 years of age.

A prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the recombinant zoster vaccine in Chinese adults ≥50 years of age.

This post-marketing surveillance study evaluated the safety of the adjuvanted recombinant zoster vaccine (RZV) in Chinese adults, given the limited country-specific safety data accumulated since the 2019 licensure of RZV in China for adults ≥ 50 years of age (YOA). This descriptive, prospective cohort study enrolled adults ≥ 50 YOA who voluntarily received RZV per routine clinical practice in six centers in China. The primary outcomes were occurrence, intensity, and causal relationship to vaccination of medically attended adverse events (MAEs) within 30 days post-any dose.

Trends in adolescent and adult vaccination in pharmacy and medical settings in the United States, 2018-2024: a database study.

Background: Pharmacies can increase access to vaccines. This study aimed to describe US trends in the proportion of adolescent and adult vaccinations administered in pharmacies from 2018 to 2024.

Research Design And Methods: Retrospective cross-sectional analysis of medical and pharmacy claims from commercial health insurance enrollees.

Bilateral Thoracic Herpes Zoster in a 62-year-old Immunocompetent Woman.

Herpes zoster (HZ), caused by the reactivation of varicella-zoster virus (VZV), typically presents as a unilateral dermatomal erythematous vesicular rash. Bilateral HZ is rare and usually associated with immunocompromise. We report the case of a 62-year-old female with no evident immunocompromise who developed bilateral thoracic HZ.

Optimization of antiviral dosing in Herpesviridae encephalitis: a promising approach to improve outcome?

Background: Despite established antiviral therapy for herpes simplex (HSV), varicella zoster (VZV) and cytomegalovirus (CMV) encephalitis, outcome remains poor.

Objectives: To assess pharmacokinetic (PK) and -dynamic (PD) data of antiviral drugs in the central nervous system (CNS) to optimize treatment of Herpesviridae encephalitis.

Sources: PUBMED search 1950 to September 2024, terms 1.

The Set up and the Triggers: An Update on the Risk Factors for Giant Cell Arteritis.

Purpose Of Review: To describe recent research relevant to factors which predispose to giant cell arteritis (GCA) and those which trigger its manifestation, with particular emphasis on the more recent and controversial associations (COVID-19, vaccination, novel medications) which have changed the medical landscape and perhaps GCA prevalence.

Recent Findings: GCA remains more prevalent in Caucasians but nevertheless affects other racial groups. Certain HLA haplotypes (i.

Long-term adverse event risks of oral JAK inhibitors versus immunomodulators: a literature review.

The long-term adverse event risks associated with oral Janus kinase (JAK) inhibitors compared to broader immunomodulators are poorly understood, with limited comparative studies available. This study aims to assess the long-term adverse event risks of oral JAK inhibitors compared to broader immunomodulators in dermatology. A PubMed search included terms such as specific drug names and "adverse events," "long-term safety," "malignancy," "cardiovascular events," and/or "infections.

Combining fire needle plus cupping with famciclovir and gabapentin in the treatment of acute herpes zoster: a revised intervention approach.

This study aimed to investigate the efficacy and safety of fire needle plus cupping (FC) combined with oral famciclovir and gabapentin for the treatment of acute-phase herpes zoster (AHZ). This study was conducted as a superiority, randomized controlled trial in which 84 patients with AHZ who met the diagnostic criteria were selected and randomly assigned to three groups on a 1:1 basis. Group A: received oral famciclovir with gabapentin treatment (FG); Group B: received fire needle plus cupping (FC) with FG.

Ultrasound-Guided Thoracic Paravertebral Injection of Platelet-Rich Plasma for the Treatment of Thoracic Herpes Zoster-Related Pain: A Study Protocol.

Background: Herpes zoster (HZ), triggered by the reactivation of the varicella-zoster virus, manifests as a painful rash known as zoster-associated pain (ZAP), which can progress to postherpetic neuralgia (PHN). This study evaluates the efficacy and safety of ultrasound-guided thoracic paravertebral injections of platelet-rich plasma (PRP) in managing acute ZAP and preventing PHN.

Methods: This is a prospective, randomized, controlled, open-label, endpoint-blinded, single-center trial involving 128 participants suffering from zoster-associated pain.